{"id":243306,"date":"2021-04-13T12:18:48","date_gmt":"2021-04-13T17:18:48","guid":{"rendered":"https:\/\/www.liveaction.org\/news\/?p=243306"},"modified":"2021-04-13T22:05:08","modified_gmt":"2021-04-14T03:05:08","slug":"fda-letter-permits-abortion-pill-by-mail-during-the-covid-19","status":"publish","type":"post","link":"https:\/\/archive.liveaction.org\/news\/fda-letter-permits-abortion-pill-by-mail-during-the-covid-19\/","title":{"rendered":"FDA to allow abortion pill distribution by mail during COVID-19 pandemic"},"content":{"rendered":"
<\/div>

A\u00a0letter<\/a> sent by the U.S. Food and Drug Administration (FDA) to the pro-abortion American College of Obstetrics and Gynecology (ACOG) indicates that the agency plans to “exercise enforcement discretion” in the dispensing of the abortion pill by mail during the COVID-19 pandemic. In other words, the FDA intends to continue to allow the distribution of these dangerous abortion drugs by mail for the duration of the pandemic.<\/p>\n

The decision follows ongoing litigation<\/a> filed by\u00a0ACOG against the FDA asserting that requiring mifepristone (the abortion pill) to be dispensed to abortion clients in person<\/em> during the COVID-19 pandemic is an undue burden.\u00a0Under FDA\u2019s REMS (Risk Evaluation and Mitigation Strategy<\/a>), the abortion pill mifepristone (used in a regimen with misoprostol) must be dispensed by a certified prescriber at an approved hospital or clinic and is prohibited from being sold online or in a pharmacy.<\/p>\n

\n
\n

BREAKING: ACOG win! The @US_FDA<\/a> Acting Commissioner Janet Woodcock has notified @ACOG<\/a> and @MySMFM<\/a> that the agency will "exercise enforcement discretion" regarding #mifepristone<\/a> through the duration of the #COVID19<\/a> public health emergency. 1\/ pic.twitter.com\/PDpJ7000bc<\/a><\/p>\n

— ACOG Action (@ACOGAction) April 13, 2021<\/a><\/p><\/blockquote>\n